Reflow Medical co‑develops endovascular devices with interventional physicians, using an iterative feedback loop to address complex peripheral artery disease and chronic total occlusions. Its portfolio, including the Spur® Stent System and Cora®/Spex® catheter platforms, aims to improve procedural efficiency and long‑term vessel patency for vascular specialists.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with complex cardiovascular disease, such as peripheral artery disease and chronic total occlusions, often lack devices that address specific anatomical challenges and provide durable clinical outcomes. Existing solutions may require multiple interventions or fail to meet physician‑identified performance criteria.
Solution
Reflow Medical partners directly with interventional physicians to identify unmet clinical needs and co‑develop high‑performance endovascular devices. Using an iterative “Innovation Algorithm,” the company refines concepts through continuous clinical feedback, ensuring that each product is validated with real‑world data. Its portfolio includes the Spur® Stent System, which has demonstrated sustained patency in peripheral artery disease trials, as well as a family of catheter platforms (Cora® and Spex®) designed for precise navigation and delivery. By focusing on physician‑inspired engineering, Reflow delivers devices that improve procedural efficiency, reduce the need for repeat interventions, and support better long‑term patient outcomes.
Target Audience
Primary customers are interventional cardiologists, vascular surgeons, and peripheral interventional radiologists who treat complex arterial disease in hospital and outpatient settings.
Features
- Physician‑driven product development cycle that incorporates clinical feedback at every stage
- Spur® Stent System with proprietary geometry and material optimized for peripheral artery disease durability
- Cora® catheter family offering flexible, low‑profile delivery for challenging vascular anatomies
- Spex® and Spex LP platforms providing high‑torque control and enhanced lesion crossing capability
- Iterative “Innovation Algorithm” that integrates pre‑clinical testing, pilot studies, and post‑market data to refine device performance
- Devices available by prescription only, ensuring use under qualified physician supervision